Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-03-20 DOI:10.1038/s41571-024-00882-2

Saman Maleki Vareki, Diwakar Davar

引用次数: 0

Abstract

The composition of the gut microbiota has emerged as a tumour-extrinsic factor that modulates response to immune-checkpoint inhibitors (ICIs), although the lack of consistency in microbiota signatures across studies has limited their value as reliable biomarkers. Herein, we discuss a recent study in which longitudinal microbiome profiling identified several taxa that are persistently enriched in patients with melanoma and a favourable response to ICIs.

查看原文本刊更多论文

鉴定接受 ICIs 治疗的黑色素瘤患者的动态微生物群特征：机遇与挑战。

肠道微生物群的组成已成为调节对免疫检查点抑制剂（ICIs）反应的肿瘤外在因素，但不同研究中微生物群特征缺乏一致性限制了它们作为可靠生物标记物的价值。在本文中，我们讨论了最近的一项研究，该研究通过纵向微生物组图谱分析确定了几个类群，这些类群在黑色素瘤患者中持续富集，并对 ICIs 有良好的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.

文献相关原料

公司名称	产品信息	采购帮参考价格